Necrosis inhibitors
AssigneeNational Institute of Biological Sciences, Beijing
InventorsZhiyuan Zhang, Xiaodong Wang, Yaning Su, Hanying Ruan, Yan Ren
Life of this patent
Estimating the term…
Loading patent…
AssigneeNational Institute of Biological Sciences, Beijing
InventorsZhiyuan Zhang, Xiaodong Wang, Yaning Su, Hanying Ruan, Yan Ren
Estimating the term…
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
A method of inhibiting necrosis, comprising contacting cells determined to be in need thereof with an amide compound that is an inhibitor of cellular necrosis, of formula:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
No references of this kind are recorded.
Amides, e.g. hydroxamic acids: having aromatic rings, e.g. colchicine, atenolol, progabide
Sulfur, selenium, or tellurium compounds, e.g. thiols: sulfides; Sulfoxides; Sulfones
Having aromatic rings, e.g. colchicine, atenolol, progabide: having the nitrogen of a carboxamide group directly attached to the aromatic ring,…
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
About 8 years 2 months of term left · ends 24 Dec 2034 (estimated)
Tumor necrosis factor alpha (TNF-α)-induced NF-κB activation plays a central role in the immune system and inflammatory responses. Receptor-interacting protein 1 (RIP1) is a multi-functional signal transducer involved in mediating nuclear factor κB (NF-κB) activation, apoptosis, and necroptosis. The kinase activity of RIP1 is critically involved in mediating necroptosis, a caspase-independent pathway of necrotic cell death. Holler et al. Nat Immunol 2000; 1: 489-495; Degterev et al. Nat Chem Biol 2008; 4: 313-321.
Necroptosis plays a role in various pathological forms of cell death, including ischemic brain injury, neurodegenerative diseases and viral infections. Dunai, et al., December 2011, Pathol. Oncol. Res.: POR 17 (4): 791-800. Necrostatin-1 (Nec-1), a small molecule inhibitor of RIP1 kinase activity, can block necroptosis. Degterev et al. Nat Chem Biol 2005; 1: 112-119.
Related patent publications include: U.S. Pat. No. 6,756,394, U.S. Pat. No. 8,278,344, US2012122889, US2009099242, US2010317701, US2011144169, US20030083386, US20120309795, WO2009023272, WO2010075290, WO2010075561, WO2012125544.
TABLE 1 Compound List 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17
2-phenylaziridine (35 mg, 0.294 mmoL) and triethylamine (59.4 mg, 0.588 mmol) were dissolved in 1.5 mL of dry CH2Cl2. 2,2-dimethylbutanoyl chloride (43.3 mg, 0.323m mol) in 1 mL of CH2Cl2 was added slowly to the solution at 0° C. under nitrogen. The mixture was stirred at room temperature for 2 h, diluted with CH2Cl2 and water. The organic layer were washed with saturated NaHCO3, brine, dried with Na2SO4 and concentrated. The residue was purified by chromatography to give compound 1 (20 mg, 31%) as an colorless oil 1HNMR(CDCl3, 400 MHz): δ7.36-7.44 (m, 5H), 5.90 (dd, 1H, J=9.2, 4.0 Hz), 3.44 (dd, 1H, J=13.6, 9.2 Hz), 3.26 (dd, 1H, J=4.0, 13.6 Hz), 1.61 (qd, 2H, J=7.6, 2.4 Hz), 1.21 (s, 3H), 1.19 (s, 3H), 0.74 (t, 3H, J=7.6 Hz). LC-MS (ESI) [M+H]+ calad for C14H19NO, 218.1; found, 218.3.
The titled compound 2 was prepared in 77% yield from 2-phenylazetidine (50 mg) and 2,2-dimethylbutanoyl chloride (55 mg) according to the procedure outlined for compound 1. 1HNMR(CDCl3, 400 MHz): δ 7.31-7.36 (m, 4H), 7.23-7.28 (m, 1H), 5.35-5.39 (m, 1H), 4.34-4.46 (m, 2H), 2.66-2.74 (m, 1H), 2.07-2.14 (m, 1H), 1.59 (q, 2H, J=7.6 Hz), 1.14 (s, 6H), 0.89 (t, 3H, J=7.6 Hz). LC-MS (ESI) [M+H]+ calad for C15H21NO, 232.2; found, 232.4.